Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A), which is an overexpressed biomarker in different tumor types and plays an important role in the development and maintenance of tumor-associated angiogenesis. Here, VEGFA is linked to neoplasm.